膀胱移行细胞癌多药耐药蛋白P-gp170的表达及意义  

Expression of multidrug resistance protein P-gp170 in bladder cancer

作　　者：袁建林[1] 王禾[1] 王鹏飞[1] 陈宝琦[1] 王中琨[1] 胡沛臻[2] 马福成[2] 李有兰[1] 

机构地区：[1]第四军医大学西京医院泌尿外科,西安710033 [2]第四军医大学西京医院病理科,西安710033

出　　处：《西安医科大学学报》2001年第1期57-58,81,共3页Journal of Xi'an Medical University(Chinese)

基　　金：军队青年基金;陕西省自然科学基金!资助项目 (No .96SM 5 0 )

摘　　要：目的　研究膀胱移行细胞癌的多药耐药性。方法　应用免疫组织化学方法检测 80例膀胱移行细胞癌和 2 0例正常膀胱粘膜组织中P gp1 70的表达。结果　 80例膀胱移行细胞癌组织P gp1 70的表达阳性率为 42 % ,明显高于正常膀胱粘膜组织 ;化疗后复发肿瘤P gp1 70阳性表达率明显高于初发肿瘤。结论　P gp1 70介导的多药耐药是膀胱癌腔内灌注化疗失败的重要原因。Objective To elucidate the multidrug resistance(MDR) in bladder transitional cell carcinoma.Methods The expression of P gp170 in 80 bladder transitional cell carcinoma specimens and 20 normal bladder samples was detected by immunohistochemistry.Results The results showed that the total positive rate of P gp170 protein in 80 cases of bladder transitional cell carcinoma was 42%,higher than those in normal bladder samples;Recurrent bladder cancer treated by chemotherapy was more likely expression than primary tumor.Conclusion The P gp170 mediated MDR may be an important cause of relapsing of bladder cancer which is treated by intracavitary perfusing chemotherapy.

关 键 词：膀胱肿瘤 P-GP170 免疫组织化学 膀胱移行细胞癌 多药耐药蛋白 

分 类 号：R737.14[医药卫生—肿瘤]